Aclarion, Inc. key statistics and ratios
In fiscal 2025, Aclarion, Inc. had return on equity of -104.8%, an operating margin of -9312.5%, debt equal to 0.0% of equity and a current ratio of 14.81. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|
| Gross margin | −14.7% | −8.0% | −0.4% | −85.2% | 9.0% | 21.8% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | — | — | <−999% | <−999% | <−999% | — |
| Return on equity | — | — | — | — | −104.8% | −61.6% |
| Return on assets | −262.0% | −294.3% | −182.8% | −305.2% | −91.6% | −58.0% |
| Asset turnover | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 |
| Current ratio | 0.10 | 2.47 | 0.40 | 0.71 | 14.81 | 16.20 |
| Debt to equity | — | 0.0% | — | 0.0% | 0.0% | 0.0% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | — | — |
| R&D as % of revenue | >999% | >999% | >999% | >999% | >999% | >999% |
| Capital spending as % of revenue | — | — | 0.0% | 11.2% | 28.4% | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | −48.1% | — | −23.6% | 26.6% | 23.2% | 9.7% | 17.7% | 32.9% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | — | — | <−999% | <−999% | — | <−999% |
| Current ratio | 2.80 | 0.71 | 21.68 | 23.81 | 17.01 | 14.81 | 19.65 | 16.20 |
| Debt to equity | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| R&D as % of revenue | >999% | >999% | >999% | >999% | >999% | >999% | >999% | >999% |
Financial health
- Short-term assets cover short-term liabilities $17m of assets due within a year against $1m of liabilities due within a year.
- Short-term assets cover long-term liabilities $17m short-term assets against $0 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Moat
Weak moat
How hard Aclarion's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -150.5% of total assets over 5 years.
- Pricing power 0 / 20
Gross margin has been a median -26.4%, moving by 30.9 percentage points (standard deviation) across 5 years.
- Durability 10 / 20
Operating margin has been a median -10056.7%; its worst year was -11592.1%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 5 years, at a median -9870.9% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).
Compare with peers
- Ispecimen Inc. statistics
- YD Bio Ltd statistics
- Quantum-si Inc statistics
- Bionexus Gene Lab Corp statistics
- Seer, Inc. statistics
Head to head: ACON vs ISPCACON vs YDESACON vs QSI
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies